Archive |
Below are extracts of articles taken from our latest SUMMER 2010 Issue.
TRACKING HTS ASSAY DEVELOPMENT TIME - opportunity for improving drug discovery
By Dr Jennifer Hartigan, Cindy Liu and William Downey
High throughput screening assays are developed more quickly now due to advances in technology, improved liquid handling and sensitive detection, as well as increased communication between scientists in high throughput labs and therapeutic areas. Increased availability of commercial reagents, target proteins and engineered cell lines will relieve current bottlenecks for further improvement.
more...
Enterprise ELNs as a foundation for preclinical drug development
By Simon Beaulah, Dr Paul Denny- Gouldson and Dr Scott Weiss
Through more effective capture and reuse of data and knowledge, we discuss how Enterprise ELNs improve inter- and intra-departmental collaboration, and support quality initiatives such as ‘Quality by Design’.
more...
Biomarkers make their mark on current research and drug development trends
By Stéphane Parent and Dr Gregory Cosentino
Biomarkers continue to become increasingly relevant in research and healthcare applications, as evidenced by the global market for products involved in their identification, validation, and use – estimated at $8.3 billion in 2007 and projected to increase to $15 billion in 20101.
more...
3D CELL CULTURE - easier said than done!
By Dr John Comley
The transition from cell culture on the flat surface of a conventional twodimensional (2D) culture vessel to a three-dimensional (3D) environment, matrix or scaffold with 3D architecture has begun, and is providing much needed support for emerging applications in tissue engineering and stem cell research.
more...
New trends and therapeutic approaches for the management of diabetic retinopathy
By Dr Didier Pruneau
Diabetes mellitus is a growing epidemic that has become a global public health problem. The long-term complications of diabetes include retinopathy, the leading cause of blindness and visual impairment in adults. more...FLUORESCENCE LIFETIME finally picking up momentum!
By Dr John Comley
There is an undoubted sense that the momentum around FLT is picking up and the recent advances in FLT discussed in this article make FLT a more attractive assay technology option today.
more...
Companion Diagnostics in the pharmaceutical industry- -part II: business models
By Dr Stephen Naylor and Toby Cole
There is an emerging consensus that the development of Companion Diagnostics appears to offer a set of tools as well as the portent of relevant biological and clinical information that addresses many of the current problems that pharmaceutical companies must overcome more...Personalised Medicine - market and regulatory landscape
By Dr Enal Razvi and Dr Patricia Hurley
Over the past several years, there has been continuing interest in the deployment of personalised medicine via the development of companion diagnostics/therapeutics. The leading edge of this discipline is in the cancer personalised medicine arena where a number of therapeutics are associated with a diagnostic entity that serves to stratify those patient populations who can benefit from the given therapeutic. Not only does this ensure optimal treatment options for patients but also streamlines costs associated with expensive therapeutics whose effects may be sub-optimal in some patients, along with the challenges of toxicity and other adverse responses. more...